Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP584960.RAa4qhjezTnhkYr0ft7QDAZr-Rg9-u8eiKRrxT2atRYgU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP584960.RAa4qhjezTnhkYr0ft7QDAZr-Rg9-u8eiKRrxT2atRYgU130_assertion type Assertion NP584960.RAa4qhjezTnhkYr0ft7QDAZr-Rg9-u8eiKRrxT2atRYgU130_head.
- NP584960.RAa4qhjezTnhkYr0ft7QDAZr-Rg9-u8eiKRrxT2atRYgU130_assertion description "[To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-1-infected, treatment-na�ve subjects through 144 weeks.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP584960.RAa4qhjezTnhkYr0ft7QDAZr-Rg9-u8eiKRrxT2atRYgU130_provenance.
- NP584960.RAa4qhjezTnhkYr0ft7QDAZr-Rg9-u8eiKRrxT2atRYgU130_assertion evidence source_evidence_literature NP584960.RAa4qhjezTnhkYr0ft7QDAZr-Rg9-u8eiKRrxT2atRYgU130_provenance.
- NP584960.RAa4qhjezTnhkYr0ft7QDAZr-Rg9-u8eiKRrxT2atRYgU130_assertion SIO_000772 25350960 NP584960.RAa4qhjezTnhkYr0ft7QDAZr-Rg9-u8eiKRrxT2atRYgU130_provenance.
- NP584960.RAa4qhjezTnhkYr0ft7QDAZr-Rg9-u8eiKRrxT2atRYgU130_assertion wasDerivedFrom befree-20150227 NP584960.RAa4qhjezTnhkYr0ft7QDAZr-Rg9-u8eiKRrxT2atRYgU130_provenance.
- NP584960.RAa4qhjezTnhkYr0ft7QDAZr-Rg9-u8eiKRrxT2atRYgU130_assertion wasGeneratedBy ECO_0000203 NP584960.RAa4qhjezTnhkYr0ft7QDAZr-Rg9-u8eiKRrxT2atRYgU130_provenance.